{
"id":"mk19_bb_en_s27",
"subspecialtyId":"en",
"title":"Osteoporosis",
"jsonContent":{
"type":"section",
"id":"mk19_bb_en_s27",
"title":{
"__html":"Osteoporosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c9459d",
"children":[
"Osteoporosis"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_en_s27_1",
"title":{
"__html":"Screening"
},
"titleNode":{
"type":"section-title",
"hlId":"db7551",
"children":[
"Screening"
]
},
"children":[
{
"type":"p",
"hlId":"0b7bfe",
"children":[
"The ",
{
"type":"abbreviation",
"title":"U.S. Preventive Services Task Force",
"children":[
"USPSTF"
]
},
" recommends screening bone mineral density with ",
{
"type":"abbreviation",
"title":"dual-energy x-ray absorptiometry",
"children":[
"DEXA"
]
},
" in women ≥65 years and in postmenopausal women <65 years who are at increased risk as determined by a formal clinical risk assessment tool (e.g., ",
{
"type":"abbreviation",
"title":"Fracture Risk Assessment Tool",
"children":[
"FRAX"
]
},
")."
]
},
{
"type":"p",
"hlId":"df799b",
"children":[
"The American College of Rheumatology recommends that patients anticipating receiving >3 months of glucocorticoid treatment should have bone mineral density testing within 6 months of starting glucocorticoid therapy, including:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"b5aa89",
"children":[
"all patients aged ≥40 years"
]
},
" ",
{
"type":"list-item",
"hlId":"039606",
"children":[
"patients aged <40 years with osteoporosis risk factors or a fragility fracture"
]
},
" "
]
},
{
"type":"p",
"hlId":"b176ff",
"children":[
"Screen men and women with risk factors for secondary osteoporosis (glucocorticoid use, hyperparathyroidism, ",
{
"type":"abbreviation",
"title":"androgen deprivation therapy",
"children":[
"ADT"
]
},
" [men], malabsorption)."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"5b7e4e",
"children":[
"Do not repeat annual DEXA in women with normal DEXA results without risk factors. The optimal screening interval is unknown."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_en_s27_2",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"96ed65",
"children":[
"Osteoporosis is characterized by an increased predisposition to fractures."
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"0c7b42",
"children":[
"DEXA T-score of −1.0 to −2.4 defines osteopenia."
]
},
" ",
{
"type":"list-item",
"hlId":"cb8ed8",
"children":[
"DEXA T-score of ≤−2.5 defines osteoporosis."
]
},
" ",
{
"type":"list-item",
"hlId":"74964a",
"children":[
"Osteoporosis is also diagnosed by a history of fragility fracture (fracture from a fall at standing height or lower)."
]
},
" "
]
},
{
"type":"p",
"hlId":"182bf7",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Causes"
]
},
" "
]
},
{
"type":"p",
"hlId":"d55b0c",
"children":[
" ",
{
"type":"alert",
"children":[
"The most common cause of osteoporosis in women is estrogen deficiency and in men is testosterone deficiency."
]
},
" "
]
},
{
"type":"p",
"hlId":"54c7e7",
"children":[
"Secondary causes include:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"466eb4",
"children":[
"hyperthyroidism, hyperparathyroidism, Cushing syndrome"
]
},
" ",
{
"type":"list-item",
"hlId":"b8f206",
"children":[
"malabsorption (Crohn disease, intestinal resection, celiac disease)"
]
},
" ",
{
"type":"list-item",
"hlId":"391272",
"children":[
"rheumatoid arthritis"
]
},
" ",
{
"type":"list-item",
"hlId":"93c595",
"children":[
"medications (excessive thyroid hormone, glucocorticoids, phenobarbital, phenytoin, thiazolidinediones)"
]
},
" ",
{
"type":"list-item",
"hlId":"ee99f7",
"children":[
"multiple myeloma"
]
},
" ",
{
"type":"list-item",
"hlId":"019561",
"children":[
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"chronic kidney disease",
"children":[
"CKD"
]
},
","
]
},
" chronic liver disease"
]
},
" ",
{
"type":"list-item",
"hlId":"a21823",
"children":[
"vitamin D deficiency"
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_en_s27_3",
"title":{
"__html":"Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"fa6a5a",
"children":[
"Testing"
]
},
"children":[
{
"type":"p",
"hlId":"701163",
"children":[
"In the absence of bone fracture, primary osteoporosis is associated with normal laboratory testing."
]
},
{
"type":"p",
"hlId":"23e0cb",
"children":[
"Reasonable tests for the evaluation of secondary osteoporosis include ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"complete blood count",
"children":[
"CBC"
]
},
";"
]
},
" ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"thyroid-stimulating hormone",
"children":[
"TSH"
]
},
";"
]
},
" calcium, phosphorus, and ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"estimated glomerular filtration rate",
"children":[
"eGFR"
]
},
";"
]
},
" liver chemistry tests; ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"erythrocyte sedimentation rate",
"children":[
"ESR"
]
},
";"
]
},
" serum 25-hydroxyvitamin D level (if vitamin D deficiency is suspected); and ",
{
"type":"abbreviation",
"title":"tissue transglutaminase",
"children":[
"tTG"
]
},
" antibodies (if celiac disease is suspected)."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_en_s27_4",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"86ddbe",
"children":[
"Encourage all patients to:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"053ae1",
"children":[
"stop smoking"
]
},
" ",
{
"type":"list-item",
"hlId":"1aaec6",
"children":[
"reduce alcohol intake"
]
},
" ",
{
"type":"list-item",
"hlId":"fc0fa0",
"children":[
"begin resistance exercises"
]
},
" ",
{
"type":"list-item",
"hlId":"37a72f",
"children":[
"supplement calcium and vitamin D intake"
]
},
" "
]
},
{
"type":"p",
"hlId":"17bf2d",
"children":[
"Indications for antiresorptive therapy:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"bce914",
"children":[
"osteoporosis"
]
},
" ",
{
"type":"list-item",
"hlId":"f1d84c",
"children":[
"osteopenia (if additional high-risk factors are present)"
]
},
" ",
{
"type":"list-item",
"hlId":"28f486",
"children":[
"previous fragility fracture"
]
},
" ",
{
"type":"list-item",
"hlId":"5a207e",
"children":[
"vertebral or hip fracture"
]
},
" "
]
},
{
"type":"p",
"hlId":"0d99dd",
"children":[
"The FRAX estimates the 10-year probability of hip fracture and major osteoporotic fracture. Antiresorptive treatment is cost effective when the risk of major osteoporotic fracture is ≥20% or the risk of hip fracture is ≥3%."
]
},
{
"type":"p",
"hlId":"44242e",
"children":[
"Treatment options:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"691be2",
"children":[
"alendronate or risedronate is first-line therapy"
]
},
" ",
{
"type":"list-item",
"hlId":"2ed7d9",
"children":[
"denosumab (monoclonal antibody that inhibits osteoclast activation) may be preferred in patients with stage 4 CKD and in those intolerant of or incompletely responding to bisphosphonates"
]
},
" "
]
},
{
"type":"p",
"hlId":"6208e9",
"children":[
"Oral bisphosphonates are contraindicated in patients with CKD or esophageal disease. ",
{
"type":"alert",
"children":[
"IV zoledronate (once yearly) is an alternative therapeutic option."
]
}
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"b26d64",
"children":[
"The effects of denosumab are not sustained when treatment is stopped, and bone loss is accelerated."
]
},
" "
]
},
{
"type":"p",
"hlId":"d45a51",
"children":[
"No recommended duration of therapy is specified. Stopping therapy after 3 years (IV therapy) or 5 years (oral therapy) is reasonable in women who have a stable ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"body mass index",
"children":[
"BMI"
]
},
","
]
},
" have no history of fracture, and are at low risk for fracture. Recommended duration of the drug holiday is unknown."
]
},
{
"type":"p",
"hlId":"5061c4",
"children":[
"Drugs for osteoporosis have various adverse effects:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"c1ae68",
"children":[
"Oral bisphosphonate therapy may lead to erosive esophagitis and atypical hip fracture."
]
},
" ",
{
"type":"list-item",
"hlId":"9affe1",
"children":[
"IV bisphosphonate therapy and denosumab can lead to osteonecrosis of the jaw."
]
},
" "
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"036675",
"children":[
"Do not use estrogen replacement therapy for osteoporosis in postmenopausal women."
]
},
" ",
{
"type":"list-item",
"hlId":"197f05",
"children":[
"IV bisphosphonates are contraindicated in patients with severe hypocalcemia and CKD."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_en_s27_5",
"title":{
"__html":"Follow-up"
},
"titleNode":{
"type":"section-title",
"hlId":"b9c20d",
"children":[
"Follow-up"
]
},
"children":[
{
"type":"p",
"hlId":"f25ad4",
"children":[
"Although no consensus exists, follow-up DEXA 24 months after beginning therapy for osteoporosis is reasonable."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_en_s27_6",
"title":{
"__html":"Test Yourself"
},
"titleNode":{
"type":"section-title",
"hlId":"7866cc",
"children":[
"Test Yourself"
]
},
"children":[
{
"type":"p",
"hlId":"5d7d98",
"class":"test",
"children":[
"An 82-year-old woman has been taking thyroid hormone since age 31 years. She has lost about 7.6 cm (3.0 in) in height. Serum TSH level is <0.01 μU/mL (normal 0.5 to 5.0 μU/mL)."
]
},
{
"type":"p",
"hlId":"3a76c0",
"class":"test_answer",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Answer:"
]
},
" ",
"For diagnosis, choose thyroid hormone–induced osteoporosis. For management, reduce the thyroid hormone dose and schedule DEXA."
]
}
]
}
]
},
"tablesContent":{
}
}